Safety Pharmacology During the COVID Pandemic

Overview

Journal J Pharmacol Toxicol Methods

Publisher Elsevier

Specialties Pharmacology
Toxicology

Date 2021 Jun 28

PMID 34182120

Authors

Michael K Pugsley

Yevgeniya Koshman

Tessa de Korte

Simon Authier

Michael J Curtis

Affiliations

Soon will be listed here.

Abstract

This editorial summarizes the content of the current themed issue of J Pharmacol Toxicol Methods derived from the 2020 Annual Safety Pharmacology Society (SPS) meeting that was held virtually September 14-17, 2020 due to the ongoing COVID-19 global pandemic. A selection of articles arising from the virtual meeting is summarized. Like previous years they continue to reflect current areas of innovation in SP including new methodologies to predict human safety, best practices for IKr current measurement, and best practice considerations for the conduct of in vivo nonclinical QT studies. The meeting included scientific content from 94 abstracts (reproduced in the current volume of J Pharmacol Toxicol Methods). This continued innovation reflects a rubric in SP that identifies problems, seeks solutions and, importantly, validates the solutions.

References

Blinova K, Stohlman J, Vicente J, Chan D, Johannesen L, Hortigon-Vinagre M . Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias. Toxicol Sci. 2016; 155(1):234-247. PMC: 6093617. DOI: 10.1093/toxsci/kfw200. View

Vargas H . A new preclinical biomarker for risk of Torsades de Pointes: drug-induced reduction of the cardiac electromechanical window. Br J Pharmacol. 2010; 161(7):1441-3. PMC: 3010557. DOI: 10.1111/j.1476-5381.2010.00980.x. View

Skinner M, Hale E, Ceuppens P, Pollard C . Differentiating multichannel block on the guinea pig ECG: Use of T-T and J-T. J Pharmacol Toxicol Methods. 2021; 111:107085. DOI: 10.1016/j.vascn.2021.107085. View

Lave T, Caruso A, Parrott N, Walz A . Translational PK/PD modeling to increase probability of success in drug discovery and early development. Drug Discov Today Technol. 2016; 21-22:27-34. DOI: 10.1016/j.ddtec.2016.11.005. View

Bujold K, Hauer-Jensen M, Donini O, Rumage A, Hartman D, Hendrickson H . Citrulline as a Biomarker for Gastrointestinal-Acute Radiation Syndrome: Species Differences and Experimental Condition Effects. Radiat Res. 2016; 186(1):71-8. PMC: 4976929. DOI: 10.1667/RR14305.1. View

Jackel S, Pipp F, Emde B, Weigt S, Vigna E, Hanschke B . l-citrulline: A preclinical safety biomarker for the small intestine in rats and dogs in repeat dose toxicity studies. J Pharmacol Toxicol Methods. 2021; 110:107068. DOI: 10.1016/j.vascn.2021.107068. View

VAN DER Linde H, Van Deuren B, Teisman A, Towart R, Gallacher D . The effect of changes in core body temperature on the QT interval in beagle dogs: a previously ignored phenomenon, with a method for correction. Br J Pharmacol. 2008; 154(7):1474-81. PMC: 2451335. DOI: 10.1038/bjp.2008.265. View

Tuntland T, Ethell B, Kosaka T, Blasco F, Zang R, Jain M . Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Front Pharmacol. 2014; 5:174. PMC: 4112793. DOI: 10.3389/fphar.2014.00174. View

Rotordam M, Obergrussberger A, Brinkwirth N, Takasuna K, Becker N, Horvath A . Reliable identification of cardiac conduction abnormalities in drug discovery using automated patch clamp II: Best practices for Nav1.5 peak current in a high throughput screening environment. J Pharmacol Toxicol Methods. 2021; 112:107125. DOI: 10.1016/j.vascn.2021.107125. View

10.

Pugsley M, Authier S, Curtis M . Principles of safety pharmacology. Br J Pharmacol. 2008; 154(7):1382-99. PMC: 2492105. DOI: 10.1038/bjp.2008.280. View

11.

Bell D, Fermini B . Use of automated patch clamp in cardiac safety assessment: past, present and future perspectives. J Pharmacol Toxicol Methods. 2021; 110:107072. DOI: 10.1016/j.vascn.2021.107072. View

12.

Valentin J, Hoffmann P, De Clerck F, Hammond T, Hondeghem L . Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J Pharmacol Toxicol Methods. 2004; 49(3):171-81. DOI: 10.1016/j.vascn.2004.03.008. View

13.

Schultze A, Anderson J, Kern T, Justus R, Lee H, Zieske L . Longitudinal studies of cardiac troponin I concentrations in serum from male cynomolgus monkeys: resting values and effects of oral and intravenous dosing on biologic variability. Vet Clin Pathol. 2015; 44(3):465-71. DOI: 10.1111/vcp.12272. View

14.

Johannesen L, Vicente J, Mason J, Sanabria C, Waite-Labott K, Hong M . Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin Pharmacol Ther. 2014; 96(5):549-58. DOI: 10.1038/clpt.2014.155. View

15.

Fletcher S, Maddock H, James R, Wallis R, Gharanei M . The cardiac work-loop technique: An in vitro model for identifying and profiling drug-induced changes in inotropy using rat papillary muscles. Sci Rep. 2020; 10(1):5258. PMC: 7093439. DOI: 10.1038/s41598-020-58935-2. View

16.

Dodson A, Mi K, Russo D, Scott C, Saulnier M, Snyder K . Aggregation and analysis of secondary pharmacology data from investigational new drug submissions at the US Food and Drug Administration. J Pharmacol Toxicol Methods. 2021; 111:107098. DOI: 10.1016/j.vascn.2021.107098. View

17.

Leishman D, Beck T, Dybdal N, Gallacher D, Guth B, Holbrook M . Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society. J Pharmacol Toxicol Methods. 2011; 65(3):93-101. DOI: 10.1016/j.vascn.2011.08.006. View

18.

Sugrue A, Noseworthy P, Kremen V, Bos J, Qiang B, Rohatgi R . Identification of Concealed and Manifest Long QT Syndrome Using a Novel T Wave Analysis Program. Circ Arrhythm Electrophysiol. 2016; 9(7). DOI: 10.1161/CIRCEP.115.003830. View

19.

Manyike P, Kharasch E, Kalhorn T, Slattery J . Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther. 2000; 67(3):275-82. DOI: 10.1067/mcp.2000.104736. View

20.

Baldrick P . Core battery safety pharmacology testing - An assessment of its utility in early drug development. J Pharmacol Toxicol Methods. 2021; 109:107055. DOI: 10.1016/j.vascn.2021.107055. View